-
The risk of foetal malformation with oral retinoids is extremely high, even when used at a low dose or for a short time during pregnancy. All oral retinoids have an associated Pregnancy Prevention Programme (PPP), which is s…
-
Updated prescribing advice provided.
-
Recent interruption to the supply of liothyronine 20 microgram tablets from Amdipharm Mercury.
-
liver-function testing recommended in patients with symptoms that may indicate liver injury.
-
Care needed to minimise risk of error, including training for patients.
-
The maximum recommended dose for simvastatin in conjunction with amlodipine and diltiazem is now 20 mg/day.
-
There have been reports of acute pancreatitis associated with drugs in the dipeptidylpeptidase-4 (DPP-4) inhibitor class of antidiabetic agents (‘gliptins’).
-
Calcitonin-containing medicines should no longer be used in treatment of osteoporosis.
-
Updated contraindications and maximum dose recommendations when taken with a number of other medicines.
-
Careful monitoring of serum sodium important, co-administration of other drugs that may increase serum sodium not recommended.
-
Following a review by the Commission on Human Medicines (CHM), the marketing authorisation (licence) for levothyroxine 100 microgram tablets manufactured by Teva has been suspended.
-
Evidence does not support any increased risk of cancer in patients who use these medicines.
-
Studies of cardiovascular risk don’t support prescribing changes.
-
Use of pioglitazone is associated with a small increased risk of bladder cancer. Healthcare professionals should be aware of new warnings and precautions for use in at-risk patients
-
Atypical femoral fractures reported rarely with bisphosphonate therapy, mainly in patients receiving long-term treatment for osteoporosis.
-
If pioglitazone is used in combination with insulin patients should be observed for signs and symptoms of heart failure, weight gain, and oedema.
-
Insufficient evidence to confirm a link between oral bisphosphonate use and an increased risk of oesophageal cancer.
-
Suspension of the marketing authorisations of rosiglitazone (Avandia, Avandamet) recommended across the European Union.
-
Aluminium can be leached from glass after contact with calcium gluconate solution, leading to a risk of exposure to aluminium. Accumulation of aluminium might have adverse effects on bone mineralisation and neurological deve…
-
Zoledronic acid is associated with reports of renal impairment and renal failure, especially in patients with pre-existing renal dysfunction or other risk factors. Renal function should be measured before each dose, and pati…
-
Contraindicated in patients with any known current cancer
-
All patients with cancer should have a dental check-up before bisphosphonate treatment.
-
Patients with existing meningioma or a history of meningioma must not be prescribed high-dose (≥25 mg per day) cyproterone acetate.
-
The European Medicines Agency has advised that no change in recommendations for use is required at present.
-
Continued monitoring of medicines with a black triangle status.
-
High intravenous doses of methylthioninium chloride (methylene blue) should be avoided for patients being treated with serotonergic antidepressants (eg, SSRIs, clomipramine, and venlafaxine).
-
There have been reports of necrotising and haemorrhagic pancreatitis in people taking exenatide some of which were fatal - stop exenatide treatment if pancreatitis is diagnosed.
-
New warnings and contraindications for ergot-derived dopamine agonists due to risk of fibrosis associated with chronic use.
-
Clinical trial results suggest an increased risk of atrial fibrillation for zoledronic acid (Aclasta▼), pamidronic acid, and possibly for alendronic acid, although the balance-risk remains favourable for bisphosphonates.
-
Do not prescribe ergots to patients who have had fibrosis in the heart, lungs, or abdomen.
-
A similar biological medicinal product (biosimilar) is a new biological product that has been developed to be similar to an existing biological product (“reference” product).
-
Healthcare professionals are encouraged to report all suspected adverse reactions (ADRs) on the yellow card porftal to melt formulations of desmopressin.
-
To avoid the risk of air embolism, these products should not be infused under pressure.
-
Increased risk of stroke in older women should be taken into account in prescribing decisions.
-
Patients should be assessed regularly due to reported cases of suicidal ideation and suicidal behaviour during treatment with duloxetine or shortly after stopping treatment.
-
Risk of early psychiatric side-effects is one of several important safety issues for healthcare professionals to discuss with patients and carers, who should seek urgent medical advice in the event of any worrying symptoms.
-
Nasal formulations of desmopressin are no longer indicated for primary nocturnal enuresis.
-
Before prescribing hormone-replacement therapy, healthcare professionals should consider carefully the potential benefits and risks for every woman
-
Healthcare professionals should warn patients that compulsive behaviour with dopamine agonists may be dose-related.
-
Patients who use products that contain maltose, xylose, or galactose should use glucose-specific monitors.